EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Monocentric experience of venetoclax‐based regimen in paediatric refractory and relapsed AML / MDS

Sophie Cousson iD, Charlotte Calvo iD, Lauriane Goldwirt, Mathieu Simonin, Julie Roupret-Serzec, Marie Émilie Dourthe iD, Marion Strullu, André Baruchel, Jean-Hugues Dalle, Benoît Brethon iD

British Journal of Haematology · 2025

DOI: 10.1111/bjh.19849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Sophie Cousson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology and Immunology Department, Robert Debré Academic Hospital, GHU AP-HP Nord Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BCL‐2 inhibitor venetoclax demonstrates promising efficacy in paediatric relapsed/refractory acute myeloid leukaemia (r/r AML). This retrospective analysis evaluated 12 patients treated with venetoclax‐based regimens under compassionate use for r/r myeloid malignancies. The overall response rate (ORR) was 41.6%, with complete response (CR) achieved in 33% of patients. Three patients successfully underwent allogeneic haematopoietic scell transplantation (HSCT) after venetoclax bridging therapy. Venetoclax demonstrated a favourable safety profile with manageable side effects. These findings suggest venetoclax's potential as a valuable therapeutic option for paediatric r/r AML, particularly for heavily pretreated patients. Further investigation in larger multicentre trials is warranted to refine treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesRetrospective StudiesHumansMaleFemaleChild, PreschoolChildSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

Bcl‐2 inhibitorpaediatric acute leukaemiarefractory or relapsed AMLvenetoclax ABT‐199

Substanzen

venetoclaxAntineoplastic AgentsSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Pediatric Hematology and Immunology Department, Robert Debré Academic Hospital, GHU AP-HP Nord Université Paris Cité, Paris, France.
  • Pharmacology Department, Saint-Louis Academic Hospital, GHU AP-HP Nord Université Paris Cité, Paris, France.
  • Pediatric Hematology Oncology Department, Sorbonne Université/Trousseau Hospital, APHP, Paris, France.
  • Department of Pharmacy, Robert Debre Academic Hospital, GHU AP-HP Nord Université Paris Cité, Paris, France.

ORCID-Profile: Sophie Cousson, Charlotte Calvo, Marie Émilie Dourthe, Benoît Brethon

Zitieren

APA

Cousson, S., Calvo, C., Goldwirt, L., Simonin, M., Roupret-Serzec, J., Dourthe, M. É., Strullu, M., Baruchel, A., Dalle, J. H., & Brethon, B. (2025). Monocentric experience of venetoclax‐based regimen in paediatric refractory and relapsed AML / MDS. British Journal of Haematology. https://doi.org/10.1111/bjh.19849

Vancouver

Cousson S, Calvo C, Goldwirt L, Simonin M, Roupret-Serzec J, Dourthe MÉ, et al. Monocentric experience of venetoclax‐based regimen in paediatric refractory and relapsed AML / MDS. British Journal of Haematology. 2025. doi:10.1111/bjh.19849

BibTeX
@article{Cousson2025,
  author = {Cousson, Sophie and Calvo, Charlotte and Goldwirt, Lauriane and Simonin, Mathieu and Roupret-Serzec, Julie and Dourthe, Marie Émilie and Strullu, Marion and Baruchel, André and Dalle, Jean-Hugues and Brethon, Benoît},
  title = {Monocentric experience of venetoclax‐based regimen in paediatric refractory and relapsed AML / MDS},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.19849}
}
Kostenlos starten →